Relationship between aspirin use of esophageal, gastric and colorectal cancer patient survival: a meta-analysis

Lin, Ju-Li; Lin, Jian-Xian; Zheng, Chao-Hui; Li, Ping; Xie, Jian-Wei; Wang, Jia-bin; Lu, Jun; Chen, Qi-Yue; Cao, Long-long; Lin, Mi; Huang, Chang-Ming

doi:10.1186/s12885-020-07117-4

BMC Cancer

Table 1 Characteristics of the included trials and particiants

From: Relationship between aspirin use of esophageal, gastric and colorectal cancer patient survival: a meta-analysis

Included Trials	Dedign	Region	database	Journal	Sample size	Period	aspirin use	Follow-up time	Surgery^a non-user/ user	Chemotherapy^b non-user/ user
gastric cancer
Spence et al. [11] 2018	Cohort study	United Kingdom	cancer registries in England	Gastroenterology	2391	1998–2012	post-diagnosis use	until September 2015	947 (50.0%) / 273 (55.0%)	720 (38.0%) / 146 (29.4%)
Spence et al. [11] 2018	Cohort study	United Kingdom	the Scottish Cancer Registry	Gastroenterology	1442	2009–2012	post-diagnosis use	until January 2015	376 (33.3%) / 124 (39.7%)	587 (51.9%) / 145 (46.5%)
Frouws et al. [7] 2017	Cohort study	Netherlands	Eindhoven Cancer Registry	British Journal of Cancer	750	Jan 1998-Dec 2011	Pre- and post-diagnosis use	NA	Unknown	Unknown
esophageal cancer
Macfarlane et al. [13] 2015	Cohort study	United Kingdom	PCCIU databaseIN Scotland	Cancer Epidemiology	1197	1996–2010	Pre- and post-diagnosis use	9	Unknown	Unknown
Spence et al. [11] 2018	Cohort study	United Kingdom	cancer registries in England	Gastroenterology	2733	1998–2012	post-diagnosis use	until September 2015	879 (40.4%) 215(38.5%)	108(50.0%) 235(42.0%)
Spence et al. [11] 2018	Cohort study	United Kingdom	the Scottish Cancer Registry	Gastroenterology	1921	2009–2012	post-diagnosis use	until January 2015	266 (18.5%) 90 (18.6%)	883 (61.5%) 256 (52.8%)
Frouws et al. [7] 2017	Cohort study	Netherlands	Eindhoven Cancer Registry	British Journal of Cancer	946	Jan 1998-Dec 2011	Pre- and post-diagnosis use	NA	Unknown	Unknown
Colorectal cancer
Chan et al. [17] 2009	Cohort study	USA	Nurses’ Health Study and the Health Professionals Follow-up Study	JAMA	1279	1980–2002	Pre- and post-diagnosis use	11.8 years	Unknown	Unknown
Liao et all [20]. 2012	Cohort study	USA	Nurses’ Health Study and Health Professionals Follow-up Study	NEJM	964	1976-July 1st2006	Pre- and post-diagnosis use	until death or January 2011	Unknown	Unknown
Walker et al. [20] 2012	Cohort study	UK	General Practice Research Database	British Journal of Cancer	13,994	1987–2010	Pre- and post-diagnosis use	1.7–3.1 years	Unknown	Unknown
Domingo et al. [18] 2013	Cohort study	UK	VICTOR trial	J Clin Oncol	896	Apr 2002-Sep 2004	post-diagnosis use	NA	All patients	430 (63.1%) 62 (55.9%) 59(65.6%)7 (50%)
McCowan et al. [19] 2013	Cohort study	Tayside, United Kingdom	Health Informatics Centre	European Journal of Cancer	2990	1st January 1997-30th December 2006	Pre- and post-diagnosis use	2.8 years	Unknown	Unknown
Kothari et al. [21] 2015	Cohort study	Australia and USA	Moffitt Cancer Center and Royal Melbourne Hospital	Acta Oncol	1487	1996–2010	post-diagnosis use	4.5 years	All patients	Unknown
Reimers et al. [5] 2014	Cohort study	Netherlands	Eindhoven Cancer Registry	JAMA Intern Med.	999	2002–2008	post-diagnosis use	until January 1, 2012or death	All patients	Unknown
Cardwell et al. [16] 2014	Case-control	UK	National Cancer Data Repository	Gastroenterology	4794	1998–2007	Pre- and post-diagnosis use	7.2 years	Unknown	Unknown
Bains et al. [6] 2016	Cohort study	Norway	Cancer Registry of Norway	J Clin Oncol	23,162	Jan 2004-Dec 2011	Pre- and post-diagnosis use	median 3.0 yearsafter CRC diagnosis	88.9% of the patients	Unknown
Frouws et al. [7] 2017	Cohort study	Netherlands	Eindhoven Cancer Registry	British Journal of Cancer	6335	Jan 1998-Dec 2011	Pre- and post-diagnosis use	NA	Unknown	Unknown
Newcomb et al. [14] 2017	Cohort study	USA, Canada,Australia	Four database	J Clin Oncol	2419	1997–2008	Pre- and post-diagnosis use	10.8 years	Unknown	Unknown
Gray et al. [23] 2018	Cohort study	UK	Scottish Cancer Registry	BMC Cancer	8391	Jan 2009 - Jan2015	Pre- and post-diagnosis use	3.6 years	2167 (34.7%) 472 (22.0%)	5908 (94.7%) 2020 (94.0%)
Joseph et al. [24] 2019	Cohort study	Hong Kong	Hong Kong Hospital	J Gastroenterol Hepatol	3292	2004–2015	post-diagnosis use	10 years	All received surgery	Unknown
Zell et al. [15] 2009	Cohort study	USA	California Teachers Study cohort	Cancer	621	Date of diagnosis to death or to December 31, 2005.	Pre-diagnosis use	2.8 years	26 (7%) 19 (8%)	361 (91%) 207 (92%)
Din et al. [4] 2010	Case–control study	UK	Study of Colorectal Cancer in Scotland	Gut	4080	to 30 April 2008	Pre-diagnosis use	NA	Unknown	Unknown
Coghill et al. [14] 2011	Cohort study	USA	Hutchinson Cancer Research Center AND SEER	Gut	1737	1997–2002	Pre-diagnosis use	8 years	Unknown	Unknown

^a: 947 (50.0%) /273 (55.0%) means 947 (50.0%) receive surgery in aspirin non-user patients and 273 (55.0%) receive surgery in aspirin user patients
^b: 720 (38.0%) /146 (29.4%) means 720 (38.0%) receive chemotherapy in aspirin non-user patients and 146 (29.4%) receive chemotherapy in aspirin user patients

Back to article page

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com